TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Time until detection of the first positive EMG signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Thriving levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: First-time success rate for insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median OLP after insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of patients with a lymph node diameter ≥5 cm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: percentage of patients with absolute lymphocyte count ≥25 × 10^9/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: percentage of patients with an indication for hospitalization due to TLS risk
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: DSM‐IV‐TR depressive syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overactive Bladder Symptom Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: 24 hour urinary frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: mental health score (MOS SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: anger-hostility score (POMS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cumulative dissipated energy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Ultrasound time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Corneal endothelial cell density (ECD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: score on the anorexia/cachexia subscale (ACS) of the FAACT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: day 60 survival
Endpoint domain: Mortality/survival
Primary endpoint: number of moves
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Avoidance of SARS-CoV-2 infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: No dose-limiting toxicities observed
Endpoint domain: Adverse events/effects
Primary endpoint: No mortalities within 30 days
Endpoint domain: Mortality/survival
Primary endpoint: Plasma 24HC concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Verbal Intelligence Quotient (VIQ) scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Performance Intelligence Quotient (PIQ) scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cerebral blood flow (peak systolic velocity, end-diastolic velocity, mean velocity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Switching antidepressant
Endpoint domain: Adverse events/effects
Primary endpoint: Receiving augmentation
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of PTSD symptoms (IES-R subscales intrusion and hyperarousal)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Alzheimer's Disease (AD)
Endpoint domain: Mortality/survival
Primary endpoint: Risk of acquiring SARS-CoV-2 infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: 1-h PPGE control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinically significant hypoglycemia rate
Endpoint domain: Adverse events/effects
Primary endpoint: Number of lung segments involved
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: lip force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: structural nonprogression (ΔmTSS ≤ 0)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sufentanil consumption in patient-controlled intravenous analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with hospitalization experience
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: SCRs towards the CS+ and GS1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of multi-domain interventions for dementia prevention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cmax for celecoxib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0‐∞ for celecoxib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax for montelukast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0‐∞ for montelukast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery rates
Endpoint domain: Mortality/survival
Primary endpoint: Symptoms of worry and anxiety improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Re-diagnosis with generalized anxiety disorder (GAD)
Endpoint domain: Adverse events/effects
Primary endpoint: Pain intensity during the first 24 hours after operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to the first analgesia request
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: burning sensation
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative incidence of pancreatic pseudocyst (PPC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Estimated human ages
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CNC word score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AzBio +10 SNR improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life improvement (HUI3 and SSQ49)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: patient-reported treatment adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: composite of all-cause death, MI, or major bleeding
Endpoint domain: Mortality/survival
Primary endpoint: Executive dysfunction symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Recompression vertebral fracture incidence
Endpoint domain: Adverse events/effects
Primary endpoint: hip muscle extensibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DHEA level at 0 h of HCG stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: serum levels of interleukin 22 (IL-22)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: incidence of hypotension, hypertension, bradycardia, nausea and vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: Seroconversion percentages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adverse events (AEs) related to vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in Visual Analog Scale Nominated Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analog Scale Nominated Activity improvement ≥50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: secondary implant stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LHQ-Br total
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CSI-Br psychological and functional symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Medication changes for drug overuse and drug underuse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diet quality (HEI-2015 total scores)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean FEC (fecal egg count)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microbiological cure at days 6-10 PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Any gastrointestinal adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: ΔTgi
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean RPE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: estimated sweat loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of LLLT as adjunct therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of IL-17 family cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: corneal surface stain (Oxford)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of readmission for worsening HF and all-cause death
Endpoint domain: Mortality/survival
Primary endpoint: Participation rates in screening
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Increase in L-BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in blood NTX
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction in serum bone-specific alkaline phosphatase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Level of stigma and discrimination toward MMT patients
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: DKV angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: knee position sense error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: YBT (Y Balance Test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total incidence of movement after administration of rocuronium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of moderate or severe movement after administration of rocuronium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total prescriptions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: repeat prescription episodes
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: degree of canal straightening post-intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amount of material removed from the canal walls
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive anxiety level
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: mean change in the ratio of villus height to crypt depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: lactulose permeability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PFSR at 12 weeks
Endpoint domain: Mortality/survival
Primary endpoint: cMV concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of relatives with PTSD-related symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Impact of Event Scale scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Hospital Anxiety and Depression Scale scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Risk of intracranial progression or death
Endpoint domain: Mortality/survival
Primary endpoint: Objective response rate in intracranial lesions (ORR-IC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: biochemical recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-year biochemical recurrence-free rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incident symptomatic HF
Endpoint domain: Mortality/survival
Primary endpoint: hospitalized/fatal HF events
Endpoint domain: Mortality/survival
Primary endpoint: relative change in eGFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: reduction in liver function markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: disappearance of signs of fatty liver
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Need for additional operations due to hemorrhagic complications
Endpoint domain: Adverse events/effects
Primary endpoint: Fasting acylcarnitine species and C4-OH carnitine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Acetylcarnitine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: healing rates of scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in signs and symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-month recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intracranial response at ≥12 wk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neural preparation associated with improvement on ADHD-subscales
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: performance measures of attention predicting treatment outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dentinal tubules penetration area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Energy produced in stance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Energy absorbed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Meeting best practice guidelines for physical activity and screen time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PSA relapse
Endpoint domain: Mortality/survival
Primary endpoint: prostate cancer death
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in disease outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: side effect burden
Endpoint domain: Adverse events/effects
Primary endpoint: Laparoscopic suturing skill
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Speed of suturing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of suturing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: performance on the smoking analog task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: back-digit task performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: platelet response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quality of life regarding physical function and fatigue
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Lowest Oxygen Saturation (LSaO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Success rate of ER
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in compliance for documenting discussions about patient smoking behaviours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in documenting the risk of progression to late AMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ODI score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Yang-deficiency body constitution score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-category change on any domain of the 5-domain NPCCSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C(max) of sofosbuvir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-t) of yimitasvir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C(max) of rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BMI reduction over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neuromotor behavior modification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Engagement with collaborative care team
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Referral to community health worker
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Urinary leakage disappearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Maximal isometric contraction of the PFMs until fatigue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Dynamic endurance of the PFM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: mean planning time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Allergen-specific IgE levels to Der p 1 and Der p 23
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Induction of IgG and IgG4 specific for HDM allergens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: global executive composite score of the BRIEF
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Non-breast cancer mortality
Endpoint domain: Mortality/survival
Primary endpoint: Breastfeeding continuation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of myelosuppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Improvement in family related outcomes
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: initial stability (ISQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean blanching rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS improvement scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Intraocular Pressure (IOP) changes during scleral lens wear
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: safety and efficacy of lenacapavir as PrEP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of failures
Endpoint domain: Mortality/survival
Primary endpoint: Quality of hand hygiene (HH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Impact of morphine on driving safety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: OABSS total score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: OABSS urgency mean score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: kidney events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in BCVA from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in CST from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lower rates of complications after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: lower rates of 90-day readmissions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: lower overall health care activity-based costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Development of syncope
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in number of warts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of comments on communication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: need of respiratory support
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: gene expression signature associated with clinical response to canakinumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: F1-score for laryngeal mass detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brunnstrom stage of the hand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BBT (Box and Block Test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NIHSS score dynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: MMSE score dynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: BDS score dynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of participants with none or mild glabellar lines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seroprotection rates for DTaP5-HB-IPV-Hib
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pyrexia rates
Endpoint domain: Adverse events/effects